Sustained Therapeutics advancing clinical trials for drug delivery platform
by CM staff
A successful Phase I clinical trial resulted in a reduction in pain scores for three quarters of participants, with the effects lasting up to four weeks from a single dose.
Photo: CNW Group/Sustained Therapeutics.
VANCOUVER — A Vancouver-based therapeutics company has received regulatory approval to begin the Phase II trial of its novel long lasting non-opioid pain medication. Sustained Therapeutics’ patented medication is designed to relieve both acute and chronic pain over long periods with fewer side effects than the current standard of care.
A successful Phase I clinical trial resulted in a reduction in pain scores for three quarters of participants, with the effects lasting up to four weeks from a single dose.
The company has received a No Objection Letter (NOL) from Health Canada to move forward with a five-centre Phase II study in treating chronic pain with this new drug. Sustained Therapeutics currently has another Phase II trial underway in acute pain. Both of these trials are using the sustained release technology.
“The NOL from Health Canada is a clear indication that our clinical work is heading in the right direction,” said Dr. Martin Gleave, Founder and Chief Medical Officer. “We’ve got a green light to start our next clinical trial and we expect patient enrollment to begin in the first quarter of 2023. This study will evaluate whether this treatment beats the current standard of care.”
